Vinisha Kota, MD
Rheumatology · North Little Rock, ARNPI 1992124291
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 221 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by Amgen at 25.5% of the total. Reporting peaked in 2023 at $1,416 and has fallen 90.9% since, to $129 in 2025. That places this record below the midpoint for rheumatology clinicians in AR, where the typical reported total is $4,419.
Across 221 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AbbVie$1K
- GSK$428
- Mallinckrodt Hospital Products Inc.$167
- Boston Scientific$141
- Upsher-smith Laboratories LLC$140
- plus $1K from 32 others
What the payments were for
- Food & beverage$4,20498%
- Education$872%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 59 | $1,095 |
| AbbVie(2 entities) | 62 | $1,034 |
| GSK | 22 | $428 |
| Mallinckrodt Hospital Products Inc. | 7 | $167 |
| Boston Scientific | 1 | $141 |
| Upsher-smith Laboratories LLC | 8 | $140 |
| UCB, Inc. | 7 | $132 |
| Janssen Scientific Affairs, LLC | 1 | $129 |
| Harmony Biosciences LLC | 4 | $91 |
| Sanofi | 4 | $75 |
| Aurinia Pharma U.S., Inc. | 4 | $72 |
| Pfizer | 3 | $59 |
| ANI Pharmaceuticals, Inc. | 2 | $55 |
| Sunovion Pharmaceuticals Inc. | 4 | $54 |
| AstraZeneca(2 entities) | 3 | $53 |
| Boehringer Ingelheim | 3 | $53 |
| Eisai Inc. | 2 | $41 |
| Novartis | 2 | $41 |
| Actelion Pharmaceuticals US, Inc. | 1 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $33 |
| Johnson & Johnson | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Neurelis, Inc. | 1 | $27 |
| Dexcom, Inc. | 2 | $25 |
| Lundbeck LLC | 1 | $24 |
| SK Life Science, Inc. | 1 | $23 |
| Banner Life Sciences, LLC | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Bioventus LLC | 1 | $20 |
| Impel Pharmaceuticals Inc. | 1 | $20 |
| United Therapeutics Corporation | 1 | $19 |
| Merck | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Optinose US, Inc. | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $14 |
| Nevro Corp. | 1 | $13 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WaveWriter Alpha Prime 16$141
- Tremfya$129
How this compares
$4,290 in reported general payments places this provider in the 45th percentile of 48 rheumatology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 26 | $740,382 |
| Humira(Cf) PenAdalimumab | 88 | $582,121 |
| RinvoqUpadacitinib | 24 | $174,974 |
| OrenciaAbatacept | 28 | $162,014 |
| HumiraAdalimumab | 22 | $147,917 |
| Humira PenAdalimumab | 17 | $114,308 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 14 | $105,964 |
| Enbrel SureclickEtanercept | 14 | $98,167 |
| EnbrelEtanercept | 12 | $88,271 |
| BenlystaBelimumab | 13 | $58,718 |
| KevzaraSarilumab | 13 | $53,073 |
| Hydroxychloroquine Sulfate | 108 | $4,819 |
| Leflunomide | 71 | $4,569 |
| MethotrexateMethotrexate Sodium | 204 | $3,051 |
| Sulfasalazine | 125 | $2,878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa, Enbrel | $1,095 | $828,65338 claims |
| AbbVieRinvoq, Humira | $1,034 | $322,89146 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $28 | $162,01428 claims |
| GSKBenlysta | $428 | $58,71813 claims |
| SanofiKevzara | $75 | $53,07313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 48 rheumatology providers in Arkansas.
Other rheumatology in North Little Rock
- Aaroop HaridasNorth Little Rock$4K
- Russell BranumFort Smith$102K
- Cummins LueLittle Rock$76K
- Shailendra SinghSearcy$67K
- Christopher SonntagFayetteville$32K
- Jasen ChiLittle Rock$30K
- Richard HoukLittle Rock$25K
- Noha MohamedConway$19K
- Columbus BrownLittle Rock$18K
- David PetrosFayetteville$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.